BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 28817462)

  • 21. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients.
    Cannatelli R; Bazarova A; Zardo D; Nardone OM; Shivaji U; Smith SCL; Gkoutos G; Ricci C; Gui XS; Ghosh S; Iacucci M
    Inflamm Bowel Dis; 2021 Apr; 27(5):647-654. PubMed ID: 32592477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.
    Cerrillo E; Beltrán B; Pous S; Echarri A; Gallego JC; Iborra M; Pamies J; Nos P
    Inflamm Bowel Dis; 2015 Jul; 21(7):1572-9. PubMed ID: 26052967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
    Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Fecal Inflammatory Markers in Crohn's Disease.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Keenan JI; Leach S; Burgess L; Aitchison A; Gorelik A; Liew D; Day AS; Gearry RB
    Inflamm Bowel Dis; 2016 May; 22(5):1086-94. PubMed ID: 26818420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.
    Lasson A; Strid H; Ohman L; Isaksson S; Olsson M; Rydström B; Ung KA; Stotzer PO
    J Crohns Colitis; 2014 Aug; 8(8):789-95. PubMed ID: 24418661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal Calprotectin Levels Are Closely Correlated with the Absence of Relevant Mucosal Lesions in Postoperative Crohn's Disease.
    Garcia-Planella E; Mañosa M; Cabré E; Marín L; Gordillo J; Zabana Y; Boix J; Sáinz S; Domènech E
    Inflamm Bowel Dis; 2016 Dec; 22(12):2879-2885. PubMed ID: 27824646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Long-term Clinical and Endoscopic Remission in Children With Crohn Disease Treated With Infliximab.
    D'Arcangelo G; Oliva S; Dilillo A; Viola F; Civitelli F; Isoldi S; Cucchiara S; Aloi M
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):841-846. PubMed ID: 30633110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.
    Suárez Ferrer C; Abadía Barno M; Martín Arranz E; Jochems A; García Ramírez L; Poza Cordón J; Jaquotot Herranz M; Cerpa Arencibia A; Martín Arranz MD
    Rev Esp Enferm Dig; 2019 Oct; 111(10):744-749. PubMed ID: 31476872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
    Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
    Reinisch W; Panaccione R; Bossuyt P; Baert F; Armuzzi A; Hébuterne X; Travis S; Danese S; Sandborn WJ; Schreiber S; Berg S; Zhou Q; Kligys K; Neimark E; Suleiman AA; D'Haens G; Colombel JF
    Inflamm Bowel Dis; 2020 Sep; 26(10):1562-1571. PubMed ID: 32105310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.
    Patel A; Panchal H; Dubinsky MC
    Inflamm Bowel Dis; 2017 Sep; 23(9):1600-1604. PubMed ID: 28590341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease.
    Penna FGC; Rosa RM; Pereira FH; Cunha PFS; Sousa SCS; Ferrari TCA; Cara C; Ferrari MLA
    Gastroenterol Hepatol; 2021 Feb; 44(2):87-95. PubMed ID: 32680729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn's disease patients with anastomotic strictures.
    Lopes S; Andrade P; Rodrigues-Pinto E; Afonso J; Macedo G; Magro F
    World J Gastroenterol; 2017 Sep; 23(35):6482-6490. PubMed ID: 29085198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.